SI1789036T1 - 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga - Google Patents
5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofagaInfo
- Publication number
- SI1789036T1 SI1789036T1 SI200531283T SI200531283T SI1789036T1 SI 1789036 T1 SI1789036 T1 SI 1789036T1 SI 200531283 T SI200531283 T SI 200531283T SI 200531283 T SI200531283 T SI 200531283T SI 1789036 T1 SI1789036 T1 SI 1789036T1
- Authority
- SI
- Slovenia
- Prior art keywords
- benzyloxyphenylthio
- imidazolidin
- fur
- dione
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60273604P | 2004-08-19 | 2004-08-19 | |
EP05786673A EP1789036B1 (en) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
PCT/US2005/029259 WO2006023562A2 (en) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1789036T1 true SI1789036T1 (sl) | 2011-09-30 |
Family
ID=35968136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200531283T SI1789036T1 (sl) | 2004-08-19 | 2005-08-17 | 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga |
Country Status (17)
Country | Link |
---|---|
US (1) | US7179831B2 (sl) |
EP (1) | EP1789036B1 (sl) |
JP (1) | JP5042833B2 (sl) |
KR (1) | KR101197325B1 (sl) |
CN (1) | CN101014338B (sl) |
AT (1) | ATE508744T1 (sl) |
AU (1) | AU2005277432B2 (sl) |
BR (1) | BRPI0514470B8 (sl) |
CA (1) | CA2577430C (sl) |
DK (1) | DK1789036T3 (sl) |
ES (1) | ES2364068T3 (sl) |
HK (1) | HK1107774A1 (sl) |
MX (1) | MX2007001940A (sl) |
NZ (1) | NZ553258A (sl) |
RU (1) | RU2391339C2 (sl) |
SI (1) | SI1789036T1 (sl) |
WO (1) | WO2006023562A2 (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2636990A1 (en) * | 2006-01-13 | 2007-07-26 | Battelle Memorial Institute | Animal model for assessing copd-related diseases |
EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
PT3503885T (pt) * | 2016-08-19 | 2022-04-19 | Foresee Pharmaceuticals Co Ltd | Composição farmacêutica e métodos de utilização |
US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
CN109803961B (zh) * | 2016-09-23 | 2021-03-23 | 科研制药株式会社 | (r)-5-(3,4-二氟苯基)-5-[(3-甲基-2-氧代吡啶-1(2h)-基)甲基]咪唑烷-2,4-二酮的制造方法及用于该制造的中间体 |
US11739080B2 (en) * | 2018-05-15 | 2023-08-29 | Foresee Pharmaceuticals Usa, Inc. | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof |
CN115667227A (zh) * | 2019-11-14 | 2023-01-31 | 逸达生物科技股份有限公司 | 基质金属蛋白酶(mmp)抑制剂及其使用方法 |
KR20240019265A (ko) * | 2021-06-08 | 2024-02-14 | 포시 파마슈티컬스 컴퍼니 리미티드 | Mmp-12 억제제의 안전한 투여 |
RU2766551C1 (ru) * | 2021-07-19 | 2022-03-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び/またはTNF−α転換酵素(TACE)の阻害剤としてのヒダントイン及び関連複素環化合物 |
EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
AU2003282920A1 (en) * | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
-
2005
- 2005-08-17 KR KR1020077006294A patent/KR101197325B1/ko active IP Right Grant
- 2005-08-17 SI SI200531283T patent/SI1789036T1/sl unknown
- 2005-08-17 MX MX2007001940A patent/MX2007001940A/es active IP Right Grant
- 2005-08-17 NZ NZ553258A patent/NZ553258A/en not_active IP Right Cessation
- 2005-08-17 CA CA2577430A patent/CA2577430C/en not_active Expired - Fee Related
- 2005-08-17 ES ES05786673T patent/ES2364068T3/es active Active
- 2005-08-17 RU RU2007105822/04A patent/RU2391339C2/ru not_active IP Right Cessation
- 2005-08-17 CN CN2005800285556A patent/CN101014338B/zh not_active Expired - Fee Related
- 2005-08-17 DK DK05786673.3T patent/DK1789036T3/da active
- 2005-08-17 JP JP2007527975A patent/JP5042833B2/ja not_active Expired - Fee Related
- 2005-08-17 BR BRPI0514470A patent/BRPI0514470B8/pt not_active IP Right Cessation
- 2005-08-17 US US11/205,954 patent/US7179831B2/en active Active
- 2005-08-17 AU AU2005277432A patent/AU2005277432B2/en not_active Ceased
- 2005-08-17 WO PCT/US2005/029259 patent/WO2006023562A2/en active Application Filing
- 2005-08-17 AT AT05786673T patent/ATE508744T1/de not_active IP Right Cessation
- 2005-08-17 EP EP05786673A patent/EP1789036B1/en not_active Not-in-force
-
2008
- 2008-02-11 HK HK08101512.9A patent/HK1107774A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0514470B8 (pt) | 2021-07-20 |
RU2007105822A (ru) | 2008-09-27 |
NZ553258A (en) | 2011-02-25 |
BRPI0514470B1 (pt) | 2021-01-05 |
ATE508744T1 (de) | 2011-05-15 |
US20060041000A1 (en) | 2006-02-23 |
WO2006023562A2 (en) | 2006-03-02 |
EP1789036A4 (en) | 2008-08-27 |
EP1789036B1 (en) | 2011-05-11 |
US7179831B2 (en) | 2007-02-20 |
CA2577430A1 (en) | 2006-03-02 |
DK1789036T3 (da) | 2011-06-27 |
JP5042833B2 (ja) | 2012-10-03 |
CA2577430C (en) | 2010-12-07 |
KR20070045330A (ko) | 2007-05-02 |
CN101014338B (zh) | 2010-06-16 |
BRPI0514470A (pt) | 2008-06-10 |
WO2006023562A3 (en) | 2006-04-20 |
KR101197325B1 (ko) | 2012-11-05 |
EP1789036A2 (en) | 2007-05-30 |
AU2005277432B2 (en) | 2011-11-24 |
AU2005277432A1 (en) | 2006-03-02 |
WO2006023562B1 (en) | 2006-06-22 |
MX2007001940A (es) | 2007-07-24 |
HK1107774A1 (en) | 2008-04-18 |
JP2008510701A (ja) | 2008-04-10 |
ES2364068T3 (es) | 2011-08-24 |
RU2391339C2 (ru) | 2010-06-10 |
CN101014338A (zh) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1789036T1 (sl) | 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga | |
IL176571A0 (en) | Substituted azole derivatives, compositions, and methods of use | |
DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
ATE452631T1 (de) | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer | |
NO20081636L (no) | FAP - inhibitorer | |
ATE416171T1 (de) | 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren | |
NO20053215D0 (no) | Pyrazolderivater med anvendelse som COX-1-inhibitorer. | |
NO20043645L (no) | Sykloalkylinhibitorer av kaliumkanal-funksjon | |
DK1776011T3 (da) | Fungicid sammensætning, indeholdende et syreamidderivat | |
FR2835186B1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
IL222698A0 (en) | Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors | |
DK2094107T3 (da) | Mykotoksin-reducerende sammensætning | |
TW200715969A (en) | Fungicidal active-compound combination | |
ATE510822T1 (de) | Kaliumkanalinhibitoren | |
ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
WO2006029398A3 (en) | All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use | |
NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
AU2003234925A1 (en) | TGF-Alpha EXPRESSION INHIBITORS | |
DE60318421D1 (de) | Trockenhefe-komposition | |
AU2003215158A1 (en) | 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | |
NO20071330L (no) | Enzyminhibitor i leukemi | |
ATE493390T1 (de) | 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren | |
WO2005113503A3 (en) | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine | |
IL160376A0 (en) | Arp as an inducer of granulocytopoiesis, uses and methods thereof | |
EA200401037A1 (ru) | Антифосфолипазный препарат |